Compulsory Licensing – The Effect on Generics, Patents and Drug-Development in Indian Pharma

Authors

  • Vikram Reddy K Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore, India

DOI:

https://doi.org/10.37591/(rrjops).v5i1.533

Abstract

 

The objective of the present study was to analyse the effect of compulsory licensing (CL) on Generics, Patents and Drug-Development in India. This analytical study was
carried out by collection of the data with respect to research questions. The data were collected from WTO, research articles, journals, ICMR and DCGI guidelines, Drugs and Cosmetics Act, WHO guidelines, TRIPS agreement, Indian Patents Act. The results revealed that expiry of three years from the date of grant of patent still remains a dilemma of whether it is best suited for pharmaceutical industry per se or not. Expiry of three years from the date of marketing approval also seems to be a good option but a bit troublesome considering the public health orientation of India. CL `s do not hamper or regress the new drug development. CL is powerful tool when utilized correctly can make sure that the innovations are utilized in a useful way and not wasted. CL is a way to protect public health. From the present study it can be concluded that the compulsory licenses are not an imminent threat to the patented drug companies. If pharmaceutical companies adopt suitable modifications to their marketing strategies, especially in developing countries keeping the economy of the state in consideration, can lead to good industrial relationships. Once the application for the grant of CL is made the outcome of the judgement need not be either granting or rejection, it can also result in ordering the patentees to cut down their prices. Price Control is also an equally powerful tool when compared with CL.

Keywords: Licence, drug and cosmetics, patents


Downloads

Published

2019-07-16

Issue

Vol. 5 No. 1 (2014)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.